MMMaiara Camotti Montanha

Maiara Camotti Montanha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maiara Camotti Montanha has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy

    by Shakir Atoyebi, Fazila Bunglawala, Nicolas Cottura, Sandra Grañana‐Castillo, Maiara Camotti Montanha, Adeniyi Olagunju, Marco Siccardi, Catriona Waitt

    Aims: Long‐acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically‐based pharmacokinetic (PBPK) modelling was used to simulate the approved dosing regimens in pregnancy and explore if Ctrough was maintained above cabotegravir and rilpivirine target concentrations (664 and 50 ng/mL, respectively).Methods: An adult PBPK model was validated using clinical data of cabotegravir and rilpivirine in nonpregnant adults. This was modified by incorporating pregnancy‐induced metabolic and physiological changes. The pregnancy PBPK model was validated with data on oral rilpivirine and raltegravir (UGT1A1 probe substrate) in pregnancy. Twelve weeks' disposition of monthly and bimonthly dosing of long‐acting cabotegravir and rilpivirine was simulated at different trimesters and foetal exposure was also estimated.Results: Predicted Ctrough at week 12 for monthly long‐acting cabotegravir was above 664 ng/mL throughout pregnancy, but below the target in 0.5% of the pregnant population in the third trimester with bimonthly long‐acting cabotegravir. Predicted Ctrough at week 12 for monthly and bimonthly long‐acting rilpivirine was below 50 ng/mL in at least 40% and over 90% of the pregnant population, respectively, throughout pregnancy. Predicted medians (range) of cord‐to‐maternal blood ratios were 1.71 (range, 1.55‐1.79) for cabotegravir and 0.88 (0.78‐0.93) for rilpivirine between weeks 38 and 40.Conclusions: Model predictions suggest that monthly long‐acting cabotegravir could maintain antiviral efficacy throughout pregnancy, but that bimonthly administration may require careful clinical evaluation. Both monthly and bimonthly long‐acting rilpivirine may not adequately maintain antiviral efficacy in pregnancy.


  • Open Access

    Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy

    by Shakir Atoyebi, Fazila Bunglawala, Nicolas Cottura, Sandra Granana-Castillo, Maiara Montanha, Marco Siccardi, Catriona Waitt

    Aim Long-acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically-based pharmacokinetic modelling (PBPK) can predict drug disposition in complex populations. Approved dosing regimens were simulated in pregnancy to explore if Ctrough was maintained above target concentrations (664 ng/ml and 50 ng/ml respectively). Methods An adult PBPK model was developed and validated using clinical data of cabotegravir and rilpivirine in non-pregnant adults. This was modified by incorporating pregnancy-induced metabolic and physiological changes. The pregnancy PBPK model was validated with data on oral rilpivirine and raltegravir (UGT1A1 probe substrate) in pregnancy. Acceptance criteria for both adult and pregnancy models was absolute average-fold error (AAFE) < 2 between clinical and simulated values. The pregnancy PBPK model was used to simulate 12 weeks’ disposition of monthly and bimonthly dosing of long-acting cabotegravir and rilpivirine, initiated at different trimesters. Results Models were successfully qualified with all AAFE values below 2. Predicted Ctrough at week 12 for both monthly and bimonthly long-acting cabotegravir was above 664 ng/ml throughout pregnancy. Similarly, predicted Ctrough at week 12 for monthly long-acting rilpivirine was above 50 ng/ml throughout pregnancy. However, for bimonthly rilpivirine administration, predicted Ctrough at week 12 were <50 ng/ml in 1, 0.5, and 2.3% of the pregnant population when initiated in first, second, and third trimester respectively. Conclusion Model predictions suggest monthly and bimonthly long-acting cabotegravir is likely to maintain antiviral efficacy throughout pregnancy. However, bimonthly long-acting rilpivirine requires careful clinical evaluation in pregnancy.

  • Open Access

    Amoxicillin dosing and pharmacokinetics in obesity for the treatment of bacterial respiratory infection secondary to COVID-19: a systematic review

    by Gisela Myrian de Lima Leite Dalla Rosa, Sandra Regina Bin Silva, Sérgio Seiji Yamada, Paulo Jorge Pereira Alves Paixão, Maiara Camotti Montanha, Elza Kimura

    Objective: To conduct a systematic review of Amoxicillin (AMX) dosing and pharmacokinetics (PK) in obese subjects for the treatment of the outpatient respiratory tract infection which may be a secondary co-infection with COVID-19. Methodology: A systematic review was performed up to January 2022 on MEDLINE, EMBASE, and Web of Science. Full-text manuscripts describing AMX dosing for respiratory infection or PK in obese children, adults, and RYGB bariatric patients treated with AMX were included. Results: A total of 179 records were screened, of which 8 met the inclusion criteria. Four studies described AMX dosing in obese children and adults, while 4 described PK in obese adults and RYGB bariatric subjects. Overall, in the dosing studies, 54% of children >20 kg and 10% <40 kg with respiratory infection were considered underdosed, according to guidelines or recommendations. Underdosing of 10% occurred in both overweight and non-obese children’s groups. For morbidly obese adults, 70% were considered underdosed. In the PK studies, obese and bariatric adult subjects showed reduced exposure compared to normal weight patients for all AMX formulations. Conclusion: More PK studies are needed to confirm the optimal dose of AMX for obese patients, particularly in children. However, considering that all obese and bariatric adults had reduced exposure compared to subjects of normal weight, 1 g 8/8h should be recommended and liquid formulations are preferable for bariatric patients. To minimize the risks of therapeutic failure and avoid toxicity, a higher threshold of doses should be prescribed for obese children.

  • A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human

    by Maiara Camotti Montanha, Alice Howarth, Doaa Ahmed Mohamed, Estelle Loier, Lauren Main, Matthias Rösslein, Christiaan Delmaar, Adriele Prina-Mello, Marco Siccardi

    The use of nanoparticles (NPs) can support an enhancement of drug distribution, resulting in increased drug penetration into key tissues. Experimental in vitro data can be integrated into computational approaches to simulate NP absorption, distribution, metabolism and elimination (ADME) processes and provide quantitative pharmacokinetic predictions. The aim of this study is to develop a novel mechanistic and physiologically based pharmacokinetic (m-PBPK) model to predict the biodistribution of NPs focusing on Doxil. The main processes underpinning NPs ADME were represented considering molecular and cellular mechanisms such as stability in biological fluids, passive permeability and uptake activity by macrophages. A whole-body m-PBPK rat and human models were designed in Simbiology v. 9.6.0 (MATLAB R2019a). The m-PBPK models were successfully qualified across doxorubicin and Doxil® in both rat and human since all PK parameters AUC0-inf, Cmax, t1/2, Vd and Cl were within twofold, with an AUC0-inf absolute average-fold error (AAFE) value of 1.23 and 1.16 and 1.76 and 1.05 for Doxorubicin and Doxil® in rat and human, respectively. The time to maximum concentration in tissues for doxorubicin in both rat and human models was before 30 min of administration, while for Doxil®, the tmax was after 24 h of administration. The organs that accumulate most NP are the spleen, liver and lungs, in both models. The m-PBPK represents a predictive platform for the integration of in vitro and formulation parameters in a physiological context to quantitatively predict the NP biodistribution. Graphical abstract Schematic diagram of the whole-body m-PBPK models developed for Doxil® in rat and human physiology.


  • Open Access

    A Physiologically Based Pharmacokinetic Model to Predict Pegylated Liposomal Doxorubicin Disposition in Rats and Human

    by Maiara Camotti Montanha, Alice Howarth, Doaa Ahmed Mohamed, Estelle Loier, Lauren Main, Matthias Rösslein, Christiaan Delmaar, Adriele Prina-Mello, Marco Siccardi

    The use of nanoparticles (NPs) can support an enhancement of drug distribution, resulting in increased drug penetration into key tissues. Experimental in vitro data can be integrated into computational approaches to simulate NP absorption, distribution, metabolism, and elimination (ADME) processes and provide quantitative pharmacokinetic predictions. The aim of this study is to develop a novel mechanistic and physiologically based pharmacokinetic (m-PBPK) model to predict the biodistribution of NPs focusing on Doxil.The main processes underpinning NPs ADME were represented considering molecular and cellular mechanisms such as stability in biological fluids, passive permeability, and uptake activity by macrophages. A whole-body m-PBPK rat and human models were designed in Simbiology v. 9.6.0 (MATLAB R2019a).The m-PBPK models was successfully qualified across doxorubicin and Doxil® in both rat and human since all PK parameters AUC0 − inf, Cmax, t1/2, Vd and Cl were within 2-fold, with an AUC0 − inf absolute average-fold error (AAFE) value of 1.23 and 1.16, and 1.76 and 1.05 for Doxorubicin and Doxil® in rat and human, respectively. The time to maximum concentration in tissues for doxorubicin in both rat and human models was before 30 minutes of administration, while for Doxil® the tmax was after 24 hours of administration. The organs that accumulate most NP are spleen, liver, and lungs, in both models.The m-PBPK represents a predictive platform for the integration of in vitro and formulation parameters in a physiological context to quantitatively predict the NP biodistribution.

  • Open Access

    PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease

    by Maiara Camotti Montanha, Nicolas Cottura, Michael Booth, Daryl Hodge, Fazila Bunglawala, Hannah Kinvig, Sandra Grañana-Castillo, Andrew Lloyd, Saye Khoo, Marco Siccardi

    The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created to simulate 100 adult individuals aged 18–60 years. Physiological changes (e.g., plasma protein concentration, liver size, CP450 expression, hepatic blood flow) and portal vein shunt were incorporated into the LD model. The changes were implemented by using the Child-Pugh (CP) classification system. DEX was qualified using clinical data in healthy adults for both oral (PO) and intravenous (IV) administrations and similarly propranolol (PRO) and midazolam (MDZ) were qualified with PO and IV clinical data in healthy and LD adults. The qualified model was subsequently used to simulate a 6 mg PO and 20 mg IV dose of DEX in patients with varying degrees of LD, with and without shunting. The PBPK model was successfully qualified across DEX, MDZ and PRO. In contrast to healthy adults, the simulated systemic clearance of DEX decreased (35%–60%) and the plasma concentrations increased (170%–400%) in patients with LD. Moreover, at higher doses of DEX, the AUC ratio between healthy/LD individuals remained comparable to lower doses. The exposure of DEX in different stages of LD was predicted through PBPK modelling, providing a rational framework to predict PK in complex clinical scenarios related to COVID-19. Model simulations suggest dose adjustments of DEX in LD patients are not necessary considering the low dose administered in the COVID-19 protocol.


  • Open Access

    PBPK modelling of dexamethasone in patients with COVID-19 and liver disease

    by Maiara Camotti Montanha, Nicolas Cottura, Michael Booth, Daryl Hodge, Fazila Bunglawala, Hannah Kinvig, Sandra Grañana-Castillo, Andrew Lloyd, Saye Khoo, Marco Siccardi

    The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created to simulate 100 adult individuals aged 18-60 years. Physiological changes (e.g., plasma protein concentration, liver size, CP450 expression, hepatic blood flow) and portal vein shunt were incorporated into the LD model. The changes were implemented by using the Child-Pugh (CP) classification system. DEX was qualified using clinical data in healthy adults for both oral (PO) and intravenous (IV) administrations and similarly propranolol (PRO) and midazolam (MDZ) were qualified with PO and IV clinical data in healthy and LD adults. The qualified model was subsequently used to simulate a 6 mg PO and 20 mg IV dose of DEX in patients with varying degrees of LD, with and without shunting. The PBPK model was successfully qualified across DEX, MDZ and PRO. In contrast to healthy adults, the simulated systemic clearance of DEX decreased (35% - 60%) and the plasma concentrations increased (170% - 400%) in patients with LD. Moreover, at higher doses of DEX, the AUC ratio between healthy/LD individuals remained comparable to lower doses. The exposure of DEX in different stages of LD was predicted through PBPK modelling, providing a rational framework to predict PK in complex clinical scenarios related to COVID-19. Model simulations suggest dose adjustments of DEX in LD patients are not necessary considering the low dose administered in the COVID-19 protocol.

  • Wastewater treatment using Mg-doped ZnO nano-semiconductors: A study of their potential use in environmental remediation

    by Angélica Gonçalves Oliveira, Jéssica de Lara Andrade, Maiara Camotti Montanha, Camilla Yara Langer Ogawa, Thábata Karoliny Formicoli de Souza Freitas, Juliana Carla Garcia Moraes, Francielle Sato, Sandro Marcio Lima, Luis Humberto da Cunha Andrade, Ana Adelina Winkler Hechenleitner, et al.


  • Pharmacokinetics of amoxicillin in obese and nonobese subjects

    by Ana Luiza P.P.D.P. Soares, Maiara C. Montanha, Conrado D.S. Alcantara, Sandra R.B. Silva, Cristina M. Kuroda, Sérgio S. Yamada, Antônio E. Nicacio, Liane Maldaner, Jesui V. Visentainer, Caroline F. Simões, et al.

    Aims: To compare the pharmacokinetics of amoxicillin (AMX) in obese and nonobese subjects, given as single dose 875‐mg tablets.Methods: A prospective, single‐centre, open‐label, clinical study was carried out involving 10 nonobese and 20 obese subjects given a dose of an AMX 875‐mg tablet. Serial blood samples were collected between 0 and 8 hours after administration of AMX and plasma levels were quantified by liquid chromatography–tandem mass spectrometry. The pharmacokinetic parameters (PK) were calculated by noncompartmental analysis and means of the 2 groups were compared using Student t‐test. Analysis of correlation between covariates and PK was performed using Pearson's correlation coefficient.Results: Ten nonobese subjects (mean age 30.6 ± 7.12 y; body mass index 21.56 ± 1.95 kg/m2) and 20 obese subjects (mean age 34.47 ± 7.03 y; body mass index 33.17 ± 2.38 kg/m2) participated in the study. Both maximum concentration (Cmax; 12.12 ± 4.06 vs. 9.66 ± 2.93 mg/L) and area under the curve (AUC)0‐inf (34.18 ± 12.94 mg.h/L vs. 26.88 ± 9.24 mg.h/L) were slightly higher in nonobese than in obese subjects, respectively, but differences were not significant. The volume of distribution (V/F) parameter was statistically significantly higher in obese compared to nonobese patients (44.20 ± 17.85 L vs. 27.57 ± 12.96 L). Statistically significant correlations were observed for several weight metrics vs. AUC, Cmax, V/F and clearance, and for creatinine clearance vs. AUC, Cmax and clearance.Conclusion: In obese subjects, the main altered PK was V/F as a consequence of greater body weight. This may result in antibiotic treatment failure if standard therapeutic regimens are administered.


  • Physiologically-Based Pharmacokinetic Model on the Oral Drug Absorption in Roux-en-Y Gastric Bypass Bariatric Patients: Amoxicillin Tablet and Suspension

    by Maiara Camotti Montanha, Andréa Diniz, Nuno Miguel Elvas Neves Silva, Elza Kimura, Paulo Paixão

    The potential of a PBPK model to predict oral Amoxicillin bioavailability, by considering the physiological changes after “Roux-en-Y gastric bypass” (RYGB) surgery in bariatric patients, was evaluated. A middle-out approach for parameter estimations was undertaken using in vitro, in situ, and in vivo data. The observed versus predicted plasma concentrations and the model sensitivity of the simulated parameters of AUC0-inf and Cmax of amoxicillin (AMX) were used to confirm the reliability of the estimation. The model considers that a drug-transporter (Transp) in the initial segments of the normal intestine plays a significant role in the AMX absorption. A lower fraction absorbed (Fabs) was observed in RYGB patients (54.43 % for suspension and 45.21 % for tablets) compared to healthy subjects (77.48 % capsule). Furthermore, the tablet formulation presented a lower dissolved fraction (Fd) and Fabs compared to the suspension formulation of AMX in RYGB patients (91.70 % and 45.21 % versus 99.92 % and 54.43 %, respectively). The AUC0-inf and Cmax were sensitive to changes in Rtintestine, PeffAMX, and Transp for both healthy and RYGB models. Additionally, AUC0-inf and Cmax were also sensitive to changes in the tlag parameter for tablet formulation in RYGB patients. The PBPK Model showed a reduction in AMX bioavailability as a consequence of reduced intestinal length after RYGB surgery. Additionally, the difference in the predicted Fd and Fabs between suspension and tablet suggests that liquid formulations are preferable in post-bariatric patients.